| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/06/2002 | EP1177175A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/06/2002 | EP1177173A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors |
| 02/06/2002 | EP1177168A1 Caspase inhibitors and the use thereof |
| 02/06/2002 | EP1177167A2 High purity (1r, 2s, 4r)-(-)-2-[(2'-(n,n-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them. |
| 02/06/2002 | EP1177166A2 Process for preparing (1r,2s,4r) -(-)-2- (2'- n,n-dimethylamino -ethoxy)] -2- phenyl] -1,7,7-tri- methyl] -bicyclo 2.2.1] heptane and pharmaceutically acceptable acid addition salts thereof |
| 02/06/2002 | EP1176985A2 Enzymatically activated polymeric drug conjugates |
| 02/06/2002 | EP1176981A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| 02/06/2002 | EP1176980A1 Ccr4 antagonists in sepsis |
| 02/06/2002 | EP1176967A1 Management of pain after joint surgery |
| 02/06/2002 | EP1176961A2 Nicotine delivery systems |
| 02/06/2002 | EP1176956A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/06/2002 | EP1176954A1 Neuroprotective composition and uses thereof |
| 02/06/2002 | EP1176948A1 Anti-nausea compositions and methods |
| 02/06/2002 | EP1176871A1 Novel beta-secretase and modulation of beta-secretase activity |
| 02/06/2002 | EP1176870A2 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 02/06/2002 | EP0863882B1 Amino substituted pyrimidines and triazines |
| 02/06/2002 | EP0771198B1 Dihydro-2,3-benzodiazepine derivatives |
| 02/06/2002 | EP0762888B1 Copolymer-1 improvements in compositions of copolymers |
| 02/06/2002 | EP0731694B1 Opioid formulations for treating pain |
| 02/06/2002 | EP0728138B1 Anthracycline derivatives |
| 02/06/2002 | CN1334875A Cell signalling polypeptides and nucleic acids |
| 02/06/2002 | CN1334813A Method for preparing (R)-(+)-3-{1-[2-(4-benzoyl-2-(3,4-difluorophenyl) morpholin-2-yl)ethyl]-4-phenylpiperdin-4-yl}-1,1-dimethylurea, its salts solvates and/or hydrates |
| 02/06/2002 | CN1334812A Piperazine derivatives |
| 02/06/2002 | CN1334809A Nonsteroidal antiinflammatories |
| 02/06/2002 | CN1334807A 1-heterocycle substd. diarylamines |
| 02/06/2002 | CN1334804A Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions contg. same |
| 02/06/2002 | CN1334800A 3,4,5-trisubstd. aryl nitrone compounds and pharmaceutical compositions contg. same |
| 02/06/2002 | CN1334797A 3,4-diamino-3-cyclobutene-1,2-dione derivs. which inhibit leukocyte adhesion mediated by VLA-4 |
| 02/06/2002 | CN1334742A Method of using lanreotide as somatostatin analogue |
| 02/06/2002 | CN1334738A Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1 |
| 02/06/2002 | CN1334729A Controlled-release dosage forms comprising zolpidem or salt thereof |
| 02/06/2002 | CN1334726A Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists |
| 02/06/2002 | CN1334271A Renaturation process for preparing human recombinant nerve growth factor |
| 02/06/2002 | CN1334099A Process for prepairng medicine to treat facial paralysis |
| 02/06/2002 | CN1334081A Parkinson's disease treating preparing contg. astrocyte function improver as active component |
| 02/06/2002 | CN1334074A Toothpaste for giving-up smoking |
| 02/06/2002 | CN1078889C Non-pepitde tachykinin receptor antagonists |
| 02/06/2002 | CN1078887C Sulfur-contg. di-tert-bytylphenol compounds useful as anti-inflammatory agents |
| 02/06/2002 | CN1078886C Inhibitor of inhibiting generation of beta-amyloid |
| 02/05/2002 | US6344570 Substituted urea derivatives as cell adhesion inhibitors |
| 02/05/2002 | US6344558 Analgesics |
| 02/05/2002 | US6344551 Contulakin-G, analogs thereof and uses therefor |
| 02/05/2002 | US6344544 Semaphorin-specific antibodies |
| 02/05/2002 | US6344474 Use of central cannabinoid receptor antagonists for regulating appetence |
| 02/05/2002 | US6344471 Diisopropyl fluorophosphate (dfp), treatment of cognitive disorders, depression, schizophrenia and anxiety. |
| 02/05/2002 | US6344470 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same |
| 02/05/2002 | US6344468 Substituted isoindolones and their use as cyclic GMP modulators in medicaments |
| 02/05/2002 | US6344452 Gastrin receptor antagonist, gastrointestinal disorders, etc |
| 02/05/2002 | US6344450 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/05/2002 | US6344449 Headache and morphine dependence |
| 02/05/2002 | US6344358 Administering somatostatin releasing agent to treat brain, psychological and nervous system disorders such as schizophrenia, amnesia, bipolar disorder, alzheimer*s disease and parkinson*s disease |
| 02/05/2002 | US6344212 Method of providing sustained analgesia with buprenorphine |
| 02/05/2002 | CA2242373C Teas for the amelioration of the effects of alcoholic drinks and processes for the production thereof |
| 02/05/2002 | CA2218289C Cd45rb binding compounds for the prevention of transplant rejection |
| 02/05/2002 | CA2217513C Pharmaceutical agents for the treatment of alzheimer's disease |
| 02/05/2002 | CA2150464C A pharmaceutical formulation for intraduodenal administration |
| 02/05/2002 | CA2123403C Acyclic ethylenediamine derivatives as substance p receptor antagonists |
| 02/05/2002 | CA2081330C 3-indolyl thioacetate derivatives |
| 02/05/2002 | CA2078578C Medical use for tachykinin antagonists |
| 02/05/2002 | CA2045290C Plaster with a high content of softening ingredients |
| 02/05/2002 | CA2019749C [.alpha.-(tert.butyl aminomethyl)-3,4-dichlorobenzyl] thioacetamide, a procedure for its preparation and its uses |
| 02/04/2002 | CA2354253A1 Polypeptides or nucleic acids encoding these of a family of g-protein coupled receptors and their use for the diagnosis or treatment of disorders, for example skin disorders and their use for the identification of pharmacologically active substances |
| 02/01/2002 | CA2354342A1 Alkyl amino acid derivatives useful as pharmaceutical agents |
| 01/31/2002 | WO2002008449A2 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 01/31/2002 | WO2002008420A2 A method of down-regulating gene expression |
| 01/31/2002 | WO2002008407A2 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008272A2 High affinity soluble interleukin-18 receptor |
| 01/31/2002 | WO2002008268A2 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008232A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 01/31/2002 | WO2002008231A2 Biologically active macrolides, compositions, and uses thereof |
| 01/31/2002 | WO2002008223A1 Indole derivatives useful for the treatment of cns disorders |
| 01/31/2002 | WO2002008222A2 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS |
| 01/31/2002 | WO2002008221A2 Capsaicin receptor ligands |
| 01/31/2002 | WO2002008220A1 2-thenoic acid (thiophene) derivatives having glutamate receptor antagonistic activity |
| 01/31/2002 | WO2002008219A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | WO2002008218A1 Cyclic substituted aminomethyl compounds and medicaments containing said compounds |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008216A1 Novel compounds and their use as glycine transport inhibitors |
| 01/31/2002 | WO2002008212A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | WO2002008210A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | WO2002008205A1 Substituted 5-alkynyl pyrimidines having neurotrophic activity |
| 01/31/2002 | WO2002008200A2 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 01/31/2002 | WO2002008189A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | WO2002008188A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | WO2002008185A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | WO2002008178A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
| 01/31/2002 | WO2002007822A2 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 01/31/2002 | WO2002007774A2 Methods for therapy of neurodegenerative disease of the brain |
| 01/31/2002 | WO2002007766A2 Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia |
| 01/31/2002 | WO2002007743A2 Piper methysticum plant extract |
| 01/31/2002 | WO2002007729A1 Non-sedating barbiturate compounds as neuroprotective agents |
| 01/31/2002 | WO2002007727A1 Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors |
| 01/31/2002 | WO2002007726A2 Treatment of movement disorders |
| 01/31/2002 | WO2002007725A1 Method for treating fibrotic diseases or other indications ic |
| 01/31/2002 | WO2002007723A1 Compositions for regulating desire for smoking |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | WO2002007677A2 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |